Pharmacotherapy and suicidality in borderline personality disorder

Abstract

Borderline personality disorder carries a heavy suicide burden: lifetime suicidal ideation ~80%, suicide attempts ~52%, suicide deaths ~6%. Medications are widely used, but antisuicidal effects remain uncertain. Umbrella review (2020–2025) plus large observational cohorts in adults. Interventions: antidepressants, antipsychotics, mood stabilizers, attention-deficit/hyperactivity disorder medications, benzodiazepines, clozapine. Outcomes: suicide attempts, suicide deaths, suicidal ideation; secondary: self-harm and emergency presentations. Across large registries (>20,000 individuals), attention-deficit/hyperactivity disorder medication was linked to 15–20% lower suicide-related outcomes and ~50% lower suicide deaths. Antidepressants were linked to 30–40% higher risk; antipsychotics to 15–20% higher risk; benzodiazepines to ~60% higher risk and ~4-fold higher suicide deaths; mood stabilizers showed no clear change. No randomized trials demonstrated reductions in suicide attempts or deaths. A small body of clozapine studies (one randomized trial; multiple uncontrolled reports) suggested reductions in severe self-harm at ~250–265 mg/day, but overall certainty was low. Clinically, prioritize structured psychotherapy; use medications for targeted symptom clusters; avoid longterm benzodiazepines; consider clozapine only in highly refractory cases with close monitoring.